DrugPatentWatch Database Preview
Profile for Canada Patent: 2994779
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
US Patent Family Members and Approved Drugs for Canada Patent: 2994779
US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
---|---|---|---|---|
Start Trial | May 1, 2026 | Novartis | AFINITOR | everolimus |
Start Trial | Aug 22, 2022 | Novartis | AFINITOR | everolimus |
Start Trial | Aug 18, 2022 | Novartis Pharm | AFINITOR DISPERZ | everolimus |
Start Trial | Aug 18, 2022 | Novartis | AFINITOR | everolimus |
>US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |